University of Limerick Institutional Repository

Expression of annexin A2 promotes cancer progression in estrogen receptor negative breast cancers

DSpace Repository

Show simple item record

dc.contributor.author Mahdi, Amira F.
dc.contributor.author Malacrida, Beatrice
dc.contributor.author Nolan, Joanne
dc.contributor.author McCumiskey, Mary E
dc.contributor.author Merrigan, Anne B.
dc.contributor.author Lal, Ashish
dc.contributor.author Tormey, Shona M.
dc.contributor.author Lowery, Aoife J.
dc.contributor.author McGourty, Kieran
dc.contributor.author Kiely, Patrick A.
dc.date.accessioned 2020-07-07T10:04:39Z
dc.date.available 2020-07-07T10:04:39Z
dc.date.issued 2020
dc.identifier.uri http://hdl.handle.net/10344/8993
dc.description peer-reviewed en_US
dc.description.abstract When breast cancer progresses to a metastatic stage, survival rates decline rapidly and it is considered incurable. Thus, deciphering the critical mechanisms of metastasis is of vital importance to develop new treatment options. We hypothesize that studying the proteins that are newly synthesized during the metastatic processes of migration and invasion will greatly enhance our understanding of breast cancer progression. We conducted a mass spectrometry screen following bioorthogonal noncanonical amino acid tagging to elucidate changes in the nascent proteome that occur during epidermal growth factor stimulation in migrating and invading cells. Annexin A2 was identified in this screen and subsequent examination of breast cancer cell lines revealed that Annexin A2 is specifically upregulated in estrogen receptor negative (ER-) cell lines. Furthermore, siRNA knockdown showed that Annexin A2 expression promotes the proliferation, wound healing and directional migration of breast cancer cells. In patients, Annexin A2 expression is increased in ER- breast cancer subtypes. Additionally, high Annexin A2 expression confers a higher probability of distant metastasis specifically for ER- patients. This work establishes a pivotal role of Annexin A2 in breast cancer progression and identifies Annexin A2 as a potential therapeutic target for the more aggressive and harder to treat ER- subtype. en_US
dc.language.iso eng en_US
dc.publisher MDPI en_US
dc.relation.ispartofseries Cells;9, 1582
dc.subject breast cancer en_US
dc.subject estrogen receptor negative en_US
dc.subject Annexin A2 en_US
dc.subject mass spectrometry en_US
dc.title Expression of annexin A2 promotes cancer progression in estrogen receptor negative breast cancers en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.identifier.doi 10.3390/cells9071582
dc.contributor.sponsor IRC en_US
dc.contributor.sponsor SFI en_US
dc.contributor.sponsor Mid-Western Cancer Foundation en_US
dc.relation.projectid GOIPG/2016/1547 en_US
dc.relation.projectid 13/CDA/2228 en_US
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


Browse

My Account

Statistics